Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kerri A. Simo is active.

Publication


Featured researches published by Kerri A. Simo.


Annals of Surgery | 2014

Microwave ablation for hepatic malignancies: a multiinstitutional analysis.

Ryan T. Groeschl; Charles Henry Caldow Pilgrim; Erin M. Hanna; Kerri A. Simo; Ryan Z. Swan; David Sindram; John B. Martinie; David A. Iannitti; Mark Bloomston; Carl Schmidt; Hooman Khabiri; Lawrence A. Shirley; Robert C.G. Martin; Susan Tsai; Kiran K. Turaga; Kathleen K. Christians; William S. Rilling; T. Clark Gamblin

Objective:This study hypothesized that tumor size, number of tumors, surgical approach, and tumor histology significantly affected microwave ablation (MWA) success and recurrence-free survival. Background:Although many hepatobiliary centers have adopted MWA, the factors that influence local control are not well described. Methods:Consecutive patients with hepatic malignancy treated by MWA were included from 4 high-volume institutions (2003–2011) and grouped by histology: hepatocellular carcinoma (HCC), colorectal liver metastases, neuroendocrine liver metastases, and other cancers. Independent significance of outcome variables was established with logistic regression and Cox proportional hazards models. Results:Four hundred fifty patients were treated with 473 procedures (139 HCC, 198 colorectal liver metastases, 61 neuroendocrine liver metastases, and 75 other) for a total of 875 tumors. Median follow-up was 18 months. Concurrent hepatectomy was performed in 178 patients (38%), and when performed was associated with greater morbidity. Complete ablation was confirmed for 839 of 865 tumors (97.0%) on follow-up cross-sectional imaging (10 were unevaluable). A surgical approach (open, laparoscopic, or percutaneous) had no significant impact on complication rates, recurrence, or survival. The local recurrence rate was 6.0% overall and was highest for HCC (10.1%, P = 0.045) and percutaneously treated lesions (14.1%, P = 0.014). In adjusted models, tumor size 3 cm or more predicted poorer recurrence-free survival (hazard ratio: 1.60, 95% CI: 1.02–2.50, P = 0.039). Conclusions:In this large data set, patients with 3 cm or more tumors showed a propensity for early recurrence, regardless of histology. Higher rates of local recurrence were noted in HCC patients, which may reflect underlying liver disease. There were no significant differences in morbidity or survival based on the surgical approach; however, local recurrence rates were highest for percutaneously ablated tumors.


Hpb | 2015

Laparoscopic microwave ablation of human liver tumours using a novel three-dimensional magnetic guidance system

David Sindram; Kerri A. Simo; Ryan Z. Swan; Sharif Razzaque; David J. Niemeyer; Ramanathan M. Seshadri; Erin M. Hanna; Iain H. McKillop; David A. Iannitti; John B. Martinie

BACKGROUND Accurate antenna placement is essential for effective microwave ablation (MWA) of lesions. Laparoscopic targeting is made particularly challenging in liver tumours by the needles trajectory as it passes through the abdominal wall into the liver. Previous optical three-dimensional guidance systems employing infrared technology have been limited by interference with the line of sight during procedures. OBJECTIVE The aim of this study was to evaluate a newly developed magnetic guidance system for laparoscopic MWA of liver tumours in a pilot study. METHODS Thirteen patients undergoing laparoscopic MWA of liver tumours gave consent to their participation in the study and were enrolled. Lesion targeting was performed using the InnerOptic AIM™ 3-D guidance system to track the real-time position and orientation of the antenna and ultrasound probe. RESULTS A total of 45 ablations were performed on 34 lesions. The median number of lesions per patient was two. The mean ± standard deviation lesion diameter was 18.0 ± 9.2 mm and the mean time to target acquisition was 3.5 min. The first-attempt success rate was 93%. There were no intraoperative or immediate postoperative complications. Over an average follow-up of 7.8 months, one patient was noted to have had an incomplete ablation, seven suffered regional recurrences, and five patients remained disease-free. CONCLUSIONS The AIM™ guidance system is an effective adjunct for laparoscopic ablation. It facilitates a high degree of accuracy and a good first-attempt success rate, and avoids the line of site interference associated with infrared systems.


Hpb | 2013

Microwave ablation using 915-MHz and 2.45-GHz systems: what are the differences?

Kerri A. Simo; Victor B. Tsirline; David Sindram; Matthew T. McMillan; Kyle J. Thompson; Ryan Z. Swan; Iain H. McKillop; John B. Martinie; David A. Iannitti

OBJECTIVES This study was conducted to evaluate differences between 915-MHz and 2.45-GHz microwave ablation (MWA) systems in the ablation of hepatic tumours. METHODS A retrospective analysis of patients undergoing hepatic tumour MWA utilizing two different systems over a 10-month period was carried out. RESULTS Data for a total of 48 patients with a mean age of 58 ± 1.24 years were analysed. A total of 124 tumours were ablated; 72 tumours were ablated with a 915-MHz system and 52 with a 2.45-GHz system. Mean tumour diameters were 1.7 ± 0.1 cm in the 915-MHz group and 2.5 ± 0.2 cm in the 2.45-GHz group (P < 0.01). Mean ablation time per burn was 8.1 ± 0.3 min in the 915-MHz group and 4.0 ± 0.1 min in the 2.45-GHz group (P < 0.01). The mean number of burns per lesion was 2.0 ± 0.1 in the 915-MHz group and 1.7 ± 0.1 in the 2.45-GHz group (P < 0.05). The mean ablation time per lesion was 9.7 ± 0.7 min in the 915-MHz group, and 6.6 ± 0.6 min in the 2.45-GHz group (P < 0.01). The 2.45-GHz system demonstrated a better correlation between ablation time and tumour size (r(2) = 0.6222) than the 915-MHz system; (r(2) = 0.0696). Mean total energy applied per lesion, and energy applied per cm, were greater with the 915-MHz system (P < 0.05 and P < 0.01, respectively). Total energy applied per lesion was similarly correlated for the 2.45-GHz (r(2) = 0.6263) and 915-MHz (r(2) = 0.7012) systems. Mean total energy applied per cm/min was greater with the 2.45-GHz system (P < 0.05). CONCLUSIONS Both 915-MHz and 2.45-GHz MWA systems achieve reproducible hepatic tumour ablation. The 2.45-GHz system achieves equivalent, but more predictable and faster ablations using a single antenna system.


Hpb | 2012

Invasive biliary mucinous cystic neoplasm: a review

Kerri A. Simo; Iain H. McKillop; W Ahrens; John B. Martinie; David A. Iannitti; David Sindram

OBJECTIVES Biliary mucinous cystic neoplasms (BMCNs) are recently redefined rare liver tumours in which insufficient recognition frequently leads to an incorrect initial or delayed diagnosis. A concise review of the subtle, sometimes non-specific, clinical, serologic and radiographic features will allow for a heightened awareness and more comprehensive understanding of these entities. METHODS Literature relating to the presentation, diagnosis, treatment, pathology and outcomes of BMCNs and published prior to March 2012 was reviewed. RESULTS Biliary mucinous cystic neoplasms most commonly occur in females (≥60%) in the fifth decade of life. Clinical symptoms, serologic markers and imaging modalities are unreliable for diagnosis of BMCNs, which leads to misdiagnosis in 55-100% of patients. Perioperative cyst aspiration is not recommended as invasive BMCNs can only be differentiated from non-invasive BMCNs by microscopic evaluation for the presence of ovarian-type stroma. Intraoperative biopsy and frozen section(s) are essential to differentiate BMCNs from other cystic liver lesions. The treatment of choice is complete excision and can result in excellent survival with initial correct diagnosis. CONCLUSIONS A low threshold for considering BMCN in the differential diagnosis of cystic liver lesions and increased attentiveness to its subtle diagnostic characteristics are imperative. The complete surgical resection of BMCNs and the use of appropriate nomenclature are necessary to improve outcomes and accurately define prognosis.


Journal of Gastrointestinal Surgery | 2012

Pyogenic Hepatic Abscess Secondary to Endolumenal Perforation of an Ingested Foreign Body

Wesley A. Glick; Kerri A. Simo; Ryan Z. Swan; David Sindram; David A. Iannitti; John B. Martinie

IntroductionPyogenic hepatic abscess induced by foreign body perforation of the gastrointestinal tract is an increasing phenomenon. Pyogenic liver abscess in itself is a challenge to treat without the complication of a foreign body.MethodsA case of a patient who developed a pyogenic hepatic abscess after unknown ingestion of a toothpick that subsequently perforated the duodenum is presented, and a literature review of pyogenic hepatic abscesses secondary to ingestion of foreign bodies and their causes, diagnosis, and treatment was performed.DiscussionEven with a thorough workup, often the diagnosis of a pyogenic hepatic abscess secondary to an endolumenal foreign body perforation is not obtained until the time of operation.


Hepatic oncology | 2014

Ablation therapy for hepatocellular carcinoma: past, present and future perspectives

David J. Niemeyer; Kerri A. Simo; David A. Iannitti; Iain H. McKillop

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and is most commonly found in the setting of liver cirrhosis. Treatment of HCC must consider both the tumors present, as well as the remaining dysfunctional liver that both hinders treatment and can produce additional HCC over time. Ablation is an evolving part of the multimodality treatment approach to HCC that can effectively destroy tumors while preserving surrounding liver parenchyma. New technologies have made ablation an indispensable tool in the treatment of all stages of HCC. This review presents the history, present technologies and future potential of ablation in the treatment of HCC.


Surgical Innovation | 2015

Optimal Ablation Volumes Are Achieved at Submaximal Power Settings in a 2.45-GHz Microwave Ablation System

David J. Niemeyer; Kerri A. Simo; Matthew T. McMillan; Ramanathan M. Seshadri; Erin M. Hanna; Jacob H. Swet; Ryan Z. Swan; David Sindram; John B. Martinie; Iain H. McKillop; David A. Iannitti

Introduction. Local ablative therapies, including microwave ablation (MWA), are common treatment modalities for in situ tumor destruction. Currently, 2.45-GHz ablation systems are gaining prominence because of the shorter application times required. The aims of this study were to determine optimal power and time to ablation volume (AbV) ratios for a new 1.8-mm–2.45-GHz antenna using ex vivo tissue models. Methods. The 1.8-mm–2.45-GHz Accu2i MWA system was employed to perform ablations in bovine liver, porcine muscle, and porcine kidney ex vivo. Whole tissues were prewarmed (35°C) and multiple ablations performed at power settings of 60 to 180 W for 2- to 6-minute time intervals. Postablation, tissues were dissected, AbVs calculated, and correlations to power and time settings made. Results. Significant increases in AbV were measured between each of the time points for a constant power setting in all 3 tissues. Increasing power settings led to significant increases in AbV at power settings ≤140 W. However, no significant increase in AbV was obtained at power settings >140 W. Conclusions. Optimal efficiency for MWA using a new 1.8-mm–2.45-GHz system is achieved at settings of ≤140 W for 6 minutes in a range of ex vivo tissue and no additional benefit occurs by increasing the power setting to 180 W in these tissues.


Hpb | 2014

Altered lysophosphatidic acid (LPA) receptor expression during hepatic regeneration in a mouse model of partial hepatectomy.

Kerri A. Simo; David J. Niemeyer; Erin M. Hanna; Jacob H. Swet; Kyle J. Thompson; David Sindram; David A. Iannitti; Ashley L. Eheim; Eugene P. Sokolov; Valentina Zuckerman; Iain H. McKillop

BACKGROUND Hepatic regeneration requires coordinated signal transduction for efficient restoration of functional liver mass. This study sought to determine changes in lysophosphatidic acid (LPA) and LPA receptor (LPAR) 1-6 expression in regenerating liver following two-thirds partial hepatectomy (PHx). METHODS Liver tissue and blood were collected from male C57BL/6 mice following PHx. Circulating LPA was measured by enzyme-linked immunosorbent assay (ELISA) and hepatic LPAR mRNA and protein expression were determined. RESULTS Circulating LPA increased 72 h after PHx and remained significantly elevated for up to 7 days post-PHx. Analysis of LPAR expression after PHx demonstrated significant increases in LPAR1, LPAR3 and LPAR6 mRNA and protein in a time-dependent manner for up to 7 days post-PHx. Conversely, LPAR2, LPAR4 and LPAR5 mRNA were barely detected in normal liver and did not significantly change after PHx. Changes in LPAR1 expression were confined to non-parenchymal cells following PHx. CONCLUSIONS Liver regeneration following PHx is associated with significant changes in circulating LPA and hepatic LPAR1, LPAR3 and LPAR6 expression in a time- and cell-dependent manner. Furthermore, changes in LPA-LPAR post-PHx occur after the first round of hepatocyte division is complete.


Archive | 2014

Techniques in Laparoscopic and Intraoperative Ultrasound Guidance

David J. Niemeyer; Kerri A. Simo; David A. Iannitti

The use of intraoperative ultrasound is beneficial for many abdominal surgical procedures. While used for other purposes, intraoperative ultrasound is an essential tool for the hepatobiliary surgeon to localize tumors and define vascular anatomy in the liver and pancreas. It is useful during resection and is essential for all but the most superficial liver tumor ablation. Ablation and biopsy of tumors requires facile use of intraoperative ultrasound guidance techniques to achieve reproducible and effective ablations with minimal chance of incomplete ablation and local tumor recurrence. Ultrasound can be utilized in both open and laparoscopic surgery with the use of a variety of transducers.


Journal of Surgical Research | 2013

Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma

Eugene P. Sokolov; Ashley L. Eheim; W Ahrens; Tracy L. Walling; Jacob H. Swet; Matthew T. McMillan; Kerri A. Simo; Kyle J. Thompson; David Sindram; Iain H. McKillop

Collaboration


Dive into the Kerri A. Simo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Sindram

Carolinas Medical Center

View shared research outputs
Top Co-Authors

Avatar

Iain H. McKillop

University of North Carolina at Charlotte

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ryan Z. Swan

Carolinas Medical Center

View shared research outputs
Top Co-Authors

Avatar

Erin M. Hanna

Carolinas Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jacob H. Swet

Carolinas Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge